KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Acadia Pharmaceuticals (ACAD) Operating Expenses (2016 - 2025)

Historic Operating Expenses for Acadia Pharmaceuticals (ACAD) over the last 17 years, with Q3 2025 value amounting to $242.9 million.

  • Acadia Pharmaceuticals' Operating Expenses rose 1102.59% to $242.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $806.2 million, marking a year-over-year decrease of 132.26%. This contributed to the annual value of $727.0 million for FY2024, which is 910.37% down from last year.
  • Acadia Pharmaceuticals' Operating Expenses amounted to $242.9 million in Q3 2025, which was up 1102.59% from $232.2 million recorded in Q2 2025.
  • Over the past 5 years, Acadia Pharmaceuticals' Operating Expenses peaked at $269.5 million during Q3 2023, and registered a low of $106.1 million during Q4 2024.
  • Over the past 5 years, Acadia Pharmaceuticals' median Operating Expenses value was $182.6 million (recorded in 2022), while the average stood at $190.6 million.
  • Its Operating Expenses has fluctuated over the past 5 years, first surged by 6677.5% in 2023, then crashed by 4589.46% in 2024.
  • Over the past 5 years, Acadia Pharmaceuticals' Operating Expenses (Quarter) stood at $175.4 million in 2021, then grew by 4.07% to $182.6 million in 2022, then rose by 7.42% to $196.1 million in 2023, then plummeted by 45.89% to $106.1 million in 2024, then skyrocketed by 128.92% to $242.9 million in 2025.
  • Its last three reported values are $242.9 million in Q3 2025, $232.2 million for Q2 2025, and $225.0 million during Q1 2025.